Jefferies lowered the firm’s price target on Progyny (PGNY) to $19 from $24 and keeps a Buy rating on the shares. The firm is lowering estimates to reflect selling season results – 1.1M member adds offset by about 700,000 from a previously announced customer loss – while also taking “a more conservative approach” to modeling utilization/mix in Q4 and FY25.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.